August 6th 2025
Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Bundled Payments and Other Cost-Management Approaches to Oncology Care
Responding to Patient Needs Central to Providing Value in Cancer Care
Cancer Trial Participants Can Successfully Self-Report Adverse Events